MSA Safety, Inc. MSA 深 滬
已收盤 09-19 16:00:00 美东时间
170.97
+0.390
+0.23%
華盛通- 最 高173.275
- 今 開171.39
- 成交量 120.56万股
- 最 低 170.56
- 昨 收 170.58
- 總市值 67.20亿
- 52周最高 182.325
- 市盈率 靜 23.73
- 換手率 3.07%
- 52周最低 126.80
- 委 比 -73.91%
- 總股本 3930.59万
- 歷史最高 198.015
- 量 比 6.38
- 振 幅 1.59%
- 歷史最低 5.27
- 每 手 1
- 風險率 9.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多喜讯丨秦川量仪重磅新品CSMM812发布
近日，秦川量仪在研发生产的复合式光学测量机OCM系列取得市场认可后，迎来系列重磅新品CSMM812发布。此新品是公司对客户需求的不断聆听、对产品能力的不断更，更...
09-19 18:04
FEMSA appoints Jose Antonio Fernández Garza-Lagüera as CEO
Fomento Económico Mexicano (NYSE:FMX) said on Wednesday that its board has appointed Jose Antonio Fernández Garza-Lagüera, currently CEO of FEMSA Proximity & Health, to become FEMSA’s Chief Executive ...
09-18 12:14
CoreWeave discloses new cloud capacity order with Nvidia
AI hyperscaler CoreWeave (NASDAQ:CRWV) disclosed a $6.3 billion new order form with Nvidia (NASDAQ:NVDA) under its existing 2023 services deal, giving Nvidia rights to buy unused data center capacity ...
09-15 21:40
Alterity Therapeutics’ ATH434 Shows Promise in Phase 2 MSA Trial
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
09-15 11:19
把“小产品”做出“大科技”，艾芬达重构全球暖通行业话语权
本文来源：时代商业研究院 作者：彭元重 9月10日，艾芬达暖通科技股份有限公司（下称“艾芬达”）正式发行上市。这家从江西走出来的“单项冠军”，在企业的20周年之...
09-10 11:52
FDA Grants Teva Pharmaceutical's Emrusolmin Fast Track Designation For Multiple System Atrophy
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options
09-09 20:31
海尔智家九大品牌“同门相残”？海外收入掺水、研发虚耗拖累盈利
（来源：明见局） 从“九子布局”的战略雄心到当前部分市场显现的协同挑战，海尔智家的多品牌战略虽面临阶段性考验，但也为后续优化升级提供了明确方向...
09-09 15:03
Alterity Therapeutics Raises $20M to Advance FDA Path for Promising Neurodegenerative Drug
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has
09-08 19:36
FEMSA to control 100% of OXXO Brazil
Fomento Económico Mexicano (NYSE:FMX) said on Thursday that it has entered into definitive agreements with Raízen to amicably terminate their joint venture in Brazil known as “Grupo Nós” that includes...
09-04 20:19
公司簡介
公司名稱
|
MSA Safety
|
行業分類
|
建筑采矿机械
|
業務描述
|
MSA Safety, Inc. engages in the development, manufacture, and sale of safety products, technology, and solutions. It operates through the following geographical segments: Americas, International, and Corporate. The Americas segment includes manufacturing, research, and development facilities in the U.S., Mexico, and Brazil. The International segment consists of companies in Europe, the Middle East, Africa, and the Asia Pacific region. The Corporate segment focuses on the general and administrative expenses incurred in its corporate headquarters. The company was founded by John Ryan and George Deike on June 14,1914 and is headquartered in Butler, PA.
|
喜讯丨秦川量仪重磅新品CSMM812发布
近日，秦川量仪在研发生产的复合式光学测量机OCM系列取得市场认可后，迎来系列重磅新品CSMM812发布。此新品是公司对客户需求的不断聆听、对产品能力的不断更，更...
09-19 18:04
FEMSA appoints Jose Antonio Fernández Garza-Lagüera as CEO
Fomento Económico Mexicano (NYSE:FMX) said on Wednesday that its board has appointed Jose Antonio Fernández Garza-Lagüera, currently CEO of FEMSA Proximity & Health, to become FEMSA’s Chief Executive ...
09-18 12:14
CoreWeave discloses new cloud capacity order with Nvidia
AI hyperscaler CoreWeave (NASDAQ:CRWV) disclosed a $6.3 billion new order form with Nvidia (NASDAQ:NVDA) under its existing 2023 services deal, giving Nvidia rights to buy unused data center capacity ...
09-15 21:40
Alterity Therapeutics’ ATH434 Shows Promise in Phase 2 MSA Trial
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
09-15 11:19
把“小产品”做出“大科技”，艾芬达重构全球暖通行业话语权
本文来源：时代商业研究院 作者：彭元重 9月10日，艾芬达暖通科技股份有限公司（下称“艾芬达”）正式发行上市。这家从江西走出来的“单项冠军”，在企业的20周年之...
09-10 11:52
FDA Grants Teva Pharmaceutical's Emrusolmin Fast Track Designation For Multiple System Atrophy
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options
09-09 20:31
海尔智家九大品牌“同门相残”？海外收入掺水、研发虚耗拖累盈利
（来源：明见局） 从“九子布局”的战略雄心到当前部分市场显现的协同挑战，海尔智家的多品牌战略虽面临阶段性考验，但也为后续优化升级提供了明确方向...
09-09 15:03
Alterity Therapeutics Raises $20M to Advance FDA Path for Promising Neurodegenerative Drug
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has
09-08 19:36
FEMSA to control 100% of OXXO Brazil
Fomento Económico Mexicano (NYSE:FMX) said on Thursday that it has entered into definitive agreements with Raízen to amicably terminate their joint venture in Brazil known as “Grupo Nós” that includes...
09-04 20:19
派息除權日
|
每股總股息
| 派息日期 |
2025-08-15
|
0.53
|
2025-09-10
|
2025-05-15
|
0.53
|
2025-06-10
|
2025-02-14
|
0.51
|
2025-03-10
|
2024-11-15
|
0.51
|
2024-12-10
|
2024-08-15
|
0.51
|
2024-09-10
|
2024-05-14
|
0.51
|
2024-06-10
|
2024-02-14
|
0.47
|
2024-03-10
|
2023-11-14
|
0.47
|
2023-12-10
|
2023-08-15
|
0.47
|
2023-09-10
|
2023-05-15
|
0.47
|
2023-06-10
|
2023-02-13
|
0.46
|
2023-03-10
|
2022-11-14
|
0.46
|
2022-12-10
|
2022-08-15
|
0.46
|
2022-09-10
|
2022-05-13
|
0.46
|
2022-06-10
|
2022-02-11
|
0.44
|
2022-03-10
|
2021-11-12
|
0.44
|
2021-12-10
|
2021-08-13
|
0.44
|
2021-09-10
|
2021-05-14
|
0.44
|
2021-06-10
|
2021-02-18
|
0.43
|
2021-03-10
|
2020-11-10
|
0.43
|
2020-12-10
|
2020-08-14
|
0.43
|
2020-09-10
|
2020-05-21
|
0.43
|
2020-06-10
|
2020-02-11
|
0.42
|
2020-03-10
|
2019-11-06
|
0.42
|
2019-12-10
|
2019-08-19
|
0.42
|
2019-09-10
|
2019-05-17
|
0.42
|
2019-06-10
|
2019-02-15
|
0.38
|
2019-03-10
|
2018-11-13
|
0.38
|
2018-12-10
|
2018-08-17
|
0.38
|
2018-09-10
|
2018-05-18
|
0.38
|
2018-06-10
|
2018-02-13
|
0.35
|
2018-03-10
|
2017-11-13
|
0.35
|
2017-12-10
|
2017-08-14
|
0.35
|
2017-09-10
|
2017-05-19
|
0.35
|
2017-06-10
|
2017-02-10
|
0.33
|
2017-03-10
|
2016-11-09
|
0.33
|
2016-12-10
|
2016-08-16
|
0.33
|
2016-09-10
|
2016-05-19
|
0.33
|
2016-06-10
|
2016-02-11
|
0.32
|
2016-03-10
|
2015-11-19
|
0.32
|
2015-12-10
|
2015-08-17
|
0.32
|
2015-09-10
|
2015-05-21
|
0.32
|
2015-06-10
|
2015-02-10
|
0.31
|
2015-03-10
|
2014-11-13
|
0.31
|
2014-12-10
|
2014-08-15
|
0.31
|
2014-09-10
|
2014-05-16
|
0.31
|
2014-06-10
|
2014-02-12
|
0.30
|
2014-03-10
|
2013-11-08
|
0.30
|
2013-12-10
|
2013-08-15
|
0.30
|
2013-09-10
|
2013-05-16
|
0.30
|
2013-06-10
|
2013-02-13
|
0.28
|
2013-03-10
|
2012-12-12
|
0.28
|
2012-12-28
|
2012-11-09
|
0.28
|
2012-12-10
|
2012-08-10
|
0.28
|
2012-09-10
|
2012-05-17
|
0.28
|
2012-06-10
|
2012-02-10
|
0.26
|
2012-03-10
|
2011-11-15
|
0.26
|
2011-12-10
|
2011-08-16
|
0.26
|
2011-09-10
|
2011-05-19
|
0.26
|
2011-06-10
|
2011-02-11
|
0.25
|
2011-03-10
|
2010-11-16
|
0.25
|
2010-12-10
|
2010-08-16
|
0.25
|
2010-09-10
|
2010-05-20
|
0.25
|
2010-06-10
|
2010-02-11
|
0.24
|
2010-03-10
|
2009-11-16
|
0.24
|
2009-12-10
|
2009-08-14
|
0.24
|
2009-09-10
|
2009-05-20
|
0.24
|
2009-06-10
|
2009-02-11
|
0.24
|
2009-03-10
|
2008-11-13
|
0.24
|
2008-12-10
|
2008-08-13
|
0.24
|
2008-09-10
|
2008-05-21
|
0.24
|
2008-06-10
|
2008-02-13
|
0.22
|
2008-03-10
|
2007-11-14
|
0.22
|
2007-12-10
|
2007-08-15
|
0.22
|
2007-09-10
|
2007-05-17
|
0.22
|
2007-06-10
|
2007-02-14
|
0.18
|
2007-03-10
|
2006-11-15
|
0.18
|
2006-12-10
|
2006-08-16
|
0.18
|
2006-09-10
|
2006-05-18
|
0.18
|
2006-06-10
|
2006-02-15
|
0.14
|
2006-03-10
|
2005-11-16
|
0.14
|
2005-12-10
|
2005-08-17
|
0.14
|
2005-09-10
|
2005-05-18
|
0.14
|
2005-06-10
|
2005-02-16
|
0.10
|
2005-03-10
|
2004-11-17
|
0.10
|
2004-12-10
|
2004-08-18
|
0.10
|
2004-09-10
|
2004-05-19
|
0.10
|
2004-06-10
|
2004-02-18
|
0.07
|
2004-03-10
|
2003-11-13
|
0.20
|
2003-12-10
|
2003-11-12
|
4.38
|
2003-11-24
|
2003-08-13
|
0.20
|
2003-09-10
|
2003-05-19
|
0.20
|
2003-06-10
|
2003-02-19
|
0.17
|
2003-03-10
|
2002-11-20
|
0.17
|
2002-12-10
|
2002-08-22
|
0.17
|
2002-09-10
|
2002-05-15
|
0.17
|
2002-06-10
|
2002-02-20
|
0.14
|
2002-03-10
|
2001-11-20
|
0.14
|
2001-12-10
|
2001-08-22
|
0.14
|
2001-09-10
|
2001-05-10
|
0.14
|
2001-06-08
|
2001-02-21
|
0.12
|
2001-03-10
|
2000-11-15
|
0.12
|
2000-12-10
|
2000-08-23
|
0.12
|
2000-09-10
|
2000-05-24
|
0.36
|
2000-06-10
|
2000-02-23
|
0.34
|
2000-03-10
|
1999-11-17
|
0.34
|
1999-12-10
|
1999-08-11
|
0.34
|
1999-09-10
|
1999-05-26
|
0.34
|
1999-06-10
|
1999-02-24
|
0.34
|
1999-03-10
|
1998-11-18
|
0.34
|
1998-12-10
|
1998-08-12
|
0.34
|
1998-09-10
|
1998-05-20
|
0.34
|
1998-06-10
|
1998-02-25
|
0.31
|
1998-03-10
|
1997-11-12
|
0.31
|
1997-12-10
|
1997-08-13
|
0.31
|
1997-09-10
|
1997-05-14
|
0.31
|
1997-06-10
|
1997-02-19
|
0.31
|
1997-03-10
|
1996-11-13
|
0.28
|
1996-12-10
|
1996-08-14
|
0.28
|
1996-09-10
|
1996-05-15
|
0.27
|
1996-06-10
|
1996-02-14
|
0.27
|
1996-03-10
|
1995-11-15
|
0.27
|
1995-12-10
|
1995-08-09
|
0.27
|
1995-09-10
|
1995-05-08
|
0.27
|
1995-06-10
|
1995-02-13
|
0.25
|
1995-03-10
|
1994-11-14
|
0.25
|
1994-12-10
|
1994-08-08
|
0.23
|
1994-09-10
|
1994-05-09
|
0.23
|
1994-06-10
|
1994-02-14
|
0.23
|
1994-03-10
|
1993-11-15
|
0.23
|
1993-12-10
|
1993-08-09
|
0.23
|
1993-09-10
|
1993-05-10
|
0.23
|
1993-06-10
|
1993-02-12
|
0.23
|
1993-03-10
|
1992-11-16
|
0.23
|
1992-12-10
|
1992-08-10
|
0.22
|
1992-09-10
|
1992-05-11
|
0.22
|
1992-06-10
|
1992-02-14
|
0.22
|
1992-03-10
|
1991-11-08
|
0.22
|
1991-12-10
|
1991-08-12
|
0.22
|
1991-09-10
|
1991-05-13
|
0.22
|
1991-06-10
|
1991-02-11
|
0.22
|
1991-03-09
|
1990-11-09
|
0.22
|
1990-12-10
|
1990-08-13
|
0.22
|
1990-09-10
|
1990-05-14
|
0.19
|
1990-06-10
|
1990-02-12
|
0.19
|
1990-03-10
|
1989-11-13
|
0.19
|
1989-12-10
|
1989-08-14
|
0.19
|
1989-09-10
|
1989-05-15
|
0.19
|
1989-06-10
|
1989-02-13
|
0.16
|
1989-03-10
|
1988-11-14
|
0.16
|
1988-12-10
|
1988-08-15
|
0.16
|
1988-09-10
|
1988-05-16
|
0.14
|
1988-06-10
|
1988-02-12
|
0.14
|
1988-03-10
|
1987-11-16
|
0.14
|
1987-12-10
|
1987-08-10
|
0.14
|
1987-09-10
|
1987-05-18
|
0.14
|
1987-06-10
|
1987-02-13
|
0.14
|
1987-03-10
|
1986-11-07
|
0.13
|
1986-12-10
|
1986-08-11
|
0.13
|
1986-09-10
|
1986-05-19
|
0.13
|
1986-06-10
|
1986-02-10
|
0.13
|
1986-03-10
|
1985-11-08
|
0.13
|
1985-12-10
|
1985-08-12
|
0.26
|
1985-09-10
|
1985-05-13
|
0.22
|
1985-06-10
|
1985-02-08
|
0.22
|
1985-03-09
|
1984-11-09
|
0.22
|
1984-12-10
|
1984-08-13
|
0.22
|
1984-09-10
|
1984-05-14
|
0.18
|
1984-06-09
|
1984-02-10
|
0.18
|
1984-03-10
|
1983-11-14
|
0.18
|
1983-12-10
|
1983-08-15
|
0.17
|
1983-09-10
|
1983-05-16
|
0.17
|
1983-06-10
|
1983-02-14
|
0.17
|
1983-03-10
|
1982-11-15
|
0.17
|
1982-12-10
|
1982-08-16
|
0.17
|
1982-09-10
|
1982-05-17
|
0.17
|
1982-06-10
|
1982-02-11
|
0.17
|
1982-03-10
|
1981-11-16
|
0.17
|
1981-12-10
|
1981-08-17
|
0.17
|
1981-09-10
|
1981-05-18
|
0.15
|
1981-06-10
|
1981-02-13
|
0.15
|
1981-03-10
|
1980-11-17
|
0.15
|
1980-12-10
|
1980-08-18
|
0.15
|
1980-09-08
|
1980-05-19
|
0.13
|
1980-06-10
|
1980-02-24
|
0.26
|
1980-03-09
|
1979-11-04
|
0.22
|
1979-12-09
|
1979-08-19
|
0.22
|
1979-09-09
|
1979-05-13
|
0.20
|
1979-06-10
|
1979-02-22
|
0.20
|
1979-03-09
|
1978-11-12
|
0.20
|
1978-12-10
|
1978-08-20
|
0.18
|
1978-09-10
|
1978-05-14
|
0.18
|
1978-06-09
|
1978-02-09
|
0.15
|
1978-03-09
|
1977-11-13
|
0.15
|
1977-12-09
|
1977-08-21
|
0.15
|
1977-09-09
|
1977-05-15
|
0.15
|
1977-06-09
|
